6838

Formosa Pharmaceuticals TPEX:6838 Stock Report

Last Price

NT$35.70

Market Cap

NT$3.5b

7D

-6.4%

1Y

n/a

Updated

17 May, 2022

Data

Company Financials
6838 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

6838 Stock Overview

Formosa Pharmaceuticals, Inc., a late-preclinical and early clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan.

Formosa Pharmaceuticals Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Formosa Pharmaceuticals
Historical stock prices
Current Share PriceNT$35.70
52 Week HighNT$61.00
52 Week LowNT$29.00
Beta0
1 Month Change-16.98%
3 Month Change-20.67%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-36.25%

Recent News & Updates

Shareholder Returns

6838TW PharmaceuticalsTW Market
7D-6.4%-2.0%-0.8%
1Yn/a3.2%4.2%

Return vs Industry: Insufficient data to determine how 6838 performed against the TW Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 6838 performed against the TW Market.

Price Volatility

Is 6838's price volatile compared to industry and market?
6838 volatility
6838 Average Weekly Movement7.3%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement4.6%
10% most volatile stocks in TW Market8.3%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 6838 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 6838's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

FoundedEmployeesCEOWebsite
201010Erick Cohttps://www.formosapharma.com

Formosa Pharmaceuticals, Inc., a late-preclinical and early clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007, an aqueous-based ophthalmic nanosuspension that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-0110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002, a topical antibiotic for infectious eye diseases, such as blepharitis; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer, as well as lung fibrosis.

Formosa Pharmaceuticals Fundamentals Summary

How do Formosa Pharmaceuticals's earnings and revenue compare to its market cap?
6838 fundamental statistics
Market CapNT$3.53b
Earnings (TTM)-NT$400.88m
Revenue (TTM)NT$28.53m

123.7x

P/S Ratio

-8.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6838 income statement (TTM)
RevenueNT$28.53m
Cost of RevenueNT$267.00k
Gross ProfitNT$28.26m
Other ExpensesNT$429.15m
Earnings-NT$400.88m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-4.06
Gross Margin99.06%
Net Profit Margin-1,405.18%
Debt/Equity Ratio0%

How did 6838 perform over the long term?

See historical performance and comparison

Valuation

Is Formosa Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


8.98x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6838's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6838's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: 6838 is unprofitable, so we can't compare its PE Ratio to the TW Pharmaceuticals industry average.

PE vs Market: 6838 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6838's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6838 is overvalued based on its PB Ratio (9x) compared to the TW Pharmaceuticals industry average (2x).


Future Growth

How is Formosa Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


51.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Formosa Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Formosa Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-82.5%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: 6838 is currently unprofitable.

Growing Profit Margin: 6838 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 6838's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 6838's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6838 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.6%).


Return on Equity

High ROE: 6838 has a negative Return on Equity (-101.93%), as it is currently unprofitable.


Financial Health

How is Formosa Pharmaceuticals's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6838's short term assets (NT$234.5M) exceed its short term liabilities (NT$19.3M).

Long Term Liabilities: 6838's short term assets (NT$234.5M) do not cover its long term liabilities (NT$276.2M).


Debt to Equity History and Analysis

Debt Level: 6838 is debt free.

Reducing Debt: 6838 has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6838 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 6838 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 17.1% each year


Dividend

What is Formosa Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6838's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6838's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6838's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6838's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6838 has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Erick Co

no data

Tenure

Dr. Erick Co serves as Director of New Drug Development at ScinoPharm Taiwan, Ltd. Dr. Erick Co is Chief Executive Officer of Formosa Pharmaceuticals, Inc. Dr. Erick Co served as Senior Scientist at Exelix...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: 6838 only recently listed within the past 12 months.


Top Shareholders

Company Information

Formosa Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Formosa Pharmaceuticals, Inc.
  • Ticker: 6838
  • Exchange: TPEX
  • Founded: 2010
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: NT$3.528b
  • Shares outstanding: 98.83m
  • Website: https://www.formosapharma.com

Number of Employees


Location

  • Formosa Pharmaceuticals, Inc.
  • No. 57, Fuxing North Road
  • 8F-6
  • Taipei
  • 105
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/17 00:00
End of Day Share Price2022/05/16 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.